Evolving paradigm of asthma management: GINA 2019–2020 updates
Short-acting β-agonists (SABAs) have been used in step 1 treatment of asthma and as rescue medication for the past 30 years, but their overuse has been associated with adverse outcomes. Increasing evidence of the benefits of combination therapy with inhaled corticosteroid (ICS) and fast-onset long-acting β-agonist (LABA) in preventing asthma exacerbations has prompted the Global Initiative for Asthma (GINA) to update the treatment strategy on asthma management. In a recent webinar, Professor J Mark FitzGerald of the University of British Columbia, Canada, provided insights into new directions for asthma management and highlighted fundamental changes in the GINA 2019–2020 reports.

New Molecule

4 New

New Formulation

2 New

New Indication

5 New

Color 1
Color 2
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in